DUBLIN, April 23, 2021 / PRNewswire / – The report, “Type 1 Diabetes – Global Drugs Forecast and Market Analysis to 2029” has been added to the offering from ResearchAndMarkets.com.
The therapeutic market for T1D within the 8MM will grow from $ 4.9 billion in 2019 with a significant average annual growth rate (CAGR) of 17.2% $ 24 billion by 2029.
In particular, the publisher expects the US market to contribute the most to and will contribute to the growth of the T1D market $ 4.3 billion Sales in 2019 (87.7% of the T1D market) and $ 20.3 billion in 2029 (84.7% of the T1D market).
The introduction of the first disease-modifying therapeutics will be the main growth drivers in the forecast period. The first preventive therapeutic for T1D, teplizumab, is expected to be launched in the United States during the forecast period. Other main drivers for the T1D market are the increased diagnosed prevalence of T1D and the inclusion of novel ultra-fast-acting and ultra-long-acting insulin analogs.
Based on the editor’s epidemiological analysis, diagnosed cases of T1D in the 8MM will increase 17.79% over the next decade, from 3,329,294 cases in 2019 to 3,921,695 cases in 2029 with an annual growth rate (AGR) of 1.78% per year in the eight major pharmaceutical markets (8 million) covered in this report, the US, 5 EU (France, Germany, Italy, Spainand UK), Japan and Canada.
The physicians surveyed, regarding the current treatment landscape, agreed that while there are a number of insulin treatment options, there are significant numbers of patients who are treated ineffectively and therefore have a considerably high unmet need within the indication.
The Key Opinion Leaders (KOLs) interviewed by the publisher emphasized the lack of a non-disease-modifying therapeutic agent that combats the autoimmune-mediated attack of beta cells in T1D patients. Other important topics include controlling blood sugar, fighting obesity, and general disease management. Despite a number of drugs currently in development, the editor’s research suggests that future achievement of these unmet needs will be modest and that drug developers will be offered relatively many opportunities to enter the T1D market.
Key highlights
- The diagnosed prevalence of T1D is expected to increase over the 10 year forecast period due to changing population demographics and a better understanding of the risk and environmental factors that can trigger the onset of T1D.
- The possible introduction of 5 disease-modifying therapeutics will increase the number of patients who can prolong their endogenous insulin secretion at the time of diagnosis to improve disease management. These drugs are expected to have a high annual cost of therapy (ACOT), a factor that contributes to their remarkable return on investment.
- The increasing trend of device integration into the treatment and management of T1D will impact the therapeutics that are successful in the market. The trend towards closed loop systems such as an artificial pancreas requires a great deal of ultrafast insulins to be brought to market and leads to closer collaboration between industries.
- Despite the multitude of insulins currently available to T1D patients, there is still room for improvement in the treatment room. Most noticeable is the need for novel treatment options for refractory patients.
Main topics covered:
1 Type 1 Diabetes: Summary
1.1 The type 1 diabetes market will grow $ 24 billion by 2029
1.2 Veteran T1D gamers use various strategies to protect insulin franchises from biosimilar erosion while new gamers invest in disease-modifying space
1.3 Current and future therapies leave significant unmet needs in the marketplace
1.4 The surge in pump usage and the increasing market entry of ultra-fast acting insulin formulations may improve the T1D treatment landscape
1.5 Remaining Possibilities for Regenerative Beta Cell Therapies
1.6 What do doctors think?
2. Introduction
3 Overview of illnesses
3.1 Etiology and pathophysiology
3.1.3 Biomarkers to monitor islet autoreactivity in type 1 diabetes
4 epidemiology
4.1 Background of illness
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast method
4.5 Epidemiological prognosis for T1D (2019-2029)
4.6 Discussion
4.6.1 Epidemiological prognosis
4.6.2 COVID-19 effects
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 US Disease Management
5.3 5EU Disease Management
5.4 Japan Disease Management
5.5 Canada Disease Management
5.6 KOL Insights into Disease Management
6 Competitive Evaluation
6.1 Overview
7 Assessment of unmet needs and opportunities
7.1 Overview
7.2 Disease Modifying Therapies – Maintenance of Beta Cells
7.3 Avoiding Hypoglycemia and Managing Blood Glucose Control
7.4 Obesity, weight management and control of the associated metabolic syndrome
7.5 Improving compliance and reducing exposure to insulin therapy
7.6 Care and education of type 1 diabetes patients
8 R&D strategies
8.1 Overview
8.2 Clinical Trial Design
9 Pipeline Assessment
10 Analysis of the pipeline evaluation
11 Current and Future Players
11.1 Overview
11.2 Deal Making Trends
11.3 Sanofi Portfolio Assessment, 2021
11.4 Eli Lilly Portfolio Assessment, 2021
11.5 Novo Nordisk Portfolio Assessment, 2021
11.6 Johnson and Johnson Portfolio Assessment, 2021
11.7 Assessment of the Lexikon Pharma portfolio, 2021
11.8 AstraZeneca, 2021
11.9 Mannkind Corporation, 2021
11.10 Valuation of Diasome Pharmaceuticals’ portfolio, 2021
11.11 Adocia Portfolio Assessment, 2021
11.12 Biocon Portfolio Assessment, 2021
11.13 Diamyd Medical Portfolio Assessment, 2021
11.14 Evaluation of the Seeland Pharma Portfolio, 2021
11.15 am vTv Therapeutics Portfolio Assessment, 2021
11.16 Evaluation of the Provention Bio Portfolio, 2021
11.17am Dompe Farmaceuti Portfolio Assessment, 2021
11.18 PolTreg Portfolio Assessment, 2021
11.19 am CellTrans Portfolio Assessment, 2021
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers – Global Problems
12.2 US
12.3 5EU
12.4 Japan
12.5 Canada
13 Appendix
Please visit https://www.researchandmarkets.com/r/hslwvx for more information on this report
Media contact:
Research and Markets
Laura Wood, Senior manager
[email protected]
For EST office hours, call + 1-917-300-0470
For Toll Free US / CAN, call + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
US Fax: 646-607-1907
Fax (outside the US): + 353-1-481-1716
SOURCE RESEARCH and Markets
similar links
http://www.researchandmarkets.com
